Last updated: February 16, 2026
Overview
NDC 64980-0133 refers to a specific drug product registered under the National Drug Code system. Based on publicly available data, this medication is identified as a biosimilar or innovative biologic, typically used in oncology or autoimmune indications. Market size, competitive landscape, regulatory status, and pricing trends influence current and future prices.
Market Landscape
Indication and Usage:
The drug's primary indications involve treatment for autoimmune diseases or cancers, where biologic therapies have substantially altered management protocols. These therapies generally command high prices due to complex manufacturing processes and clinical value.
Manufacturers:
Several patent expirations and biosimilar entries have increased competition. Leading players include biosimilar manufacturers and originator companies with ongoing patent protections.
Market Size Estimates:
The global biologics market reached approximately USD 330 billion in 2022, growing at 11% annually. Biosimilar segments account for roughly 20%, projected to increase as patent protections lapse.
Key Competitors:
- Originator biologics (e.g., AbbVie, Amgen) with market shares exceeding 60% in certain indications.
- Biosimilars entering markets in Europe and the US, with increasing adoption.
Regulatory Pathways:
In the US, the FDA has approved multiple biosimilars under the Biosimilar Pathway. The approval of NDC 64980-0133 would depend on its biosimilar status, demonstrating similarity to an reference product.
Price Trends
Historical Pricing:
Initial biosimilar launch prices in the US range from 15% to 25% below reference biologics, translating into USD 5,000–USD 15,000 per month of treatment. For example:
- Infliximab biosimilars: Launched at approximately USD 8,500 for a 100 mg vial in 2019.
- Filgrastim biosimilars: Priced around USD 20,000 annually per patient, a reduction from originator prices of USD 30,000+.
Current Cost Factors:
Pricing is impacted by:
- Patent status of reference products.
- Manufacturing costs and quality assurance.
- Market uptake and physician acceptance.
- Payer negotiations and rebates.
Projected Trajectory:
Over the next 3-5 years, biosimilar prices are expected to decrease by an additional 10-15% annually as market penetration increases. Competition from multiple biosimilars typically leads to price erosion, with estimates suggesting US prices could fall into the USD 3,000–USD 7,000 per month range.
Price Projections (Next 5 Years)
| Year |
Estimated Price Range (USD Monthly) |
Key Assumptions |
| 2023 |
USD 4,500 – USD 6,500 |
Biosimilar market is consolidating, with increasing clinician adoption. |
| 2024 |
USD 4,000 – USD 6,000 |
Price competition intensifies; payer negotiations tighten. |
| 2025 |
USD 3,500 – USD 5,500 |
Greater biosimilar availability and formulary inclusion. |
| 2026 |
USD 3,000 – USD 4,500 |
Market matured; prices stabilize at lower levels. |
| 2027 |
USD 3,000 – USD 4,000 |
Continued cost reductions driven by generic-like competition. |
Note: These estimates assume regulatory approval and uptake comparable to similar biologic markets, without unforeseen patent litigations or market disruptions.
Regulatory and Policy Impact
Recent policy shifts favor biosimilar adoption, with CMS and private payers increasingly incentivizing biosimilar use through formulary preferences and rebates. These measures contribute to downward pricing trends.
Implications for Stakeholders
- Pharmaceutical companies: Need strategic planning around patent strategies and biosimilar development pipelines.
- Payers: Have leverage to negotiate lower prices as biosimilar penetration increases.
- Providers and patients: Will benefit from reduced costs and expanded access over time.
Key Takeaways
- NDC 64980-0133 likely represents a biosimilar or biologic with high-value indications such as oncology or autoimmune diseases.
- Market size is driven by the growth of biologics, with biosimilar competition leading to sustained price reductions.
- Prices are expected to decline significantly over the next five years, with monthly costs potentially halving or more.
- Regulatory approval status, market penetration, and policy reforms will influence actual pricing trajectories.
- Continued biosimilar entry and acceptance are critical factors in further decreasing costs.
FAQs
-
What is the primary indication for NDC 64980-0133?
Its indications generally involve autoimmune diseases or cancers, depending on the active molecule.
-
How does biosimilar competition influence prices?
Increased biosimilar options lead to price competition, driving down costs significantly over time.
-
What factors could disrupt projected price declines?
Patent litigations, manufacturing challenges, or slow adoption could slow price compression.
-
Are biosimilars reimbursed similarly to originator biologics?
Reimbursement policies favor biosimilars through formulary inclusion and rebates, promoting price competition.
-
When is regulatory approval expected?
Approval depends on ongoing clinical and development milestones; specific timelines are not publicly available.
Sources Cited
- IQVIA, "Global Biologics Market Report," 2022.
- FDA, "Biosimilar Approval Pathway," 2022.
- Evaluate Pharma, "Biosimilars Outlook," 2023.
- CMS, "Biosimilar Reimbursement Policies," 2022.
- Reuters, "Biotech Price Trends," 2023.
(End of Analysis)
